All In Biotech

Drug Trial Radar · NCT06423794

BHV-7000 Open-Label Extension Bipolar Mania Study

A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Bipolar I Disorder

Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

94

Actual

Start

Jun 24, 2024

Primary completion

Apr 25, 2025

Study completion Apr 25, 2025

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

Conditions

  • Bipolar Disorder

Interventions

  • BHV-7000Drug

    BHV-7000 75 mg taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: Up to 52 weeks
  2. Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medicationTime frame: Up to 52 weeks
  3. Number of Participants With Vital Sign AbnormalitiesTime frame: Up to 52 weeks
  4. Number of Participants With Electrocardiogram (ECG) Abnormalities specific to QTc elevationTime frame: Up to 52 weeks

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Pillar Clinical Research, LLC

    Bentonville, Arkansas

  • WIRG

    Little Rock, Arkansas

  • WRN

    Rogers, Arkansas

  • Advanced Research Center, Inc.

    Anaheim, California

  • CIT LA

    Bellflower, California

  • ProScience Research Group

    Culver City, California

  • Cenexel CNS

    Garden Grove, California

  • Synergy San Diego

    Lemon Grove, California

  • NRC Research Institute

    Orange, California

  • CIT IE

    Riverside, California

  • Cenexel CNS

    Torrance, California

  • Segal Trials - Larkin Behavioral Health Services-Inpatient & Early Phase Site

    Hollywood, Florida

  • Cenexel - RCA

    Hollywood, Florida

  • LCC Medical Research Inst

    Miami, Florida

  • Floridian Neuroscience Institute

    Miami Lakes, Florida

  • Segal Trials - Miami Lakes Medical Research-Inpatient & Early Phase Site

    Miami Lakes, Florida

  • Neuroscience Research Institute

    West Palm Beach, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • CenExel iResearch, LLC

    Decatur, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • Uptown Research Institute

    Chicago, Illinois

  • Pillar Clinical Research

    Chicago, Illinois

  • CBH Health

    Gaithersburg, Maryland

  • Precise Clinical Research

    Flowood, Mississippi

  • Arch Clinical Trials

    St Louis, Missouri

  • Hassman Research Institute

    Marlton, New Jersey

  • RBA

    Staten Island, New York

  • Midwest Clinical Research Center

    Dayton, Ohio

  • NBCR

    North Canton, Ohio

  • Community Clinical Research, Inc.

    Austin, Texas

  • InSite Clinical Research, LLC

    DeSoto, Texas

  • Pillar Clinical Research, LLC

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.